TRANSCEND CLL 004 is a clinical trial that assesses a type of CAR T-cell therapy in patients suffering relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
<h3>What is CAR T-cell therapy?</h3>
The chimeric antigen receptor (CAR) T-cell therapy is a gene therapy based on genetic engineering to produce T cells that are able to target specific antigens.
The chimeric antigen receptor (CAR) T-cell therapy may result very useful to kill specific cancer cells.
In conclusion, TRANSCEND CLL 004 is a clinical trial that assesses a type of CAR T-cell therapy in patients suffering relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Learn more about gene therapy here:
brainly.com/question/315648
#SPJ1
